dr. michael birrer treatments targeting either vegf or ang2 in gynecologic cancers
Published 8 years ago • 132 plays • Length 1:32Download video MP4
Download video MP3
Similar videos
-
42:00
prospects for targeted therapy in ovarian cancer - by michael birrer, md, phd
-
2:34
dr. birrer on other targets in ovarian cancer
-
3:16
dr. michael birrer on bevacizumab in ovarian cancers
-
1:16
dr. birrer on the need for novel treatment options in cervical cancer
-
0:50
dr. birrer on challenges with patient demographics in cervical cancer
-
0:51
michael j. birrer, md, phd, elaborates on the outcomes from the forward i study
-
13:46
choosing between vegf and egfr targeted therapy in mcrc
-
1:11
claudication
-
1:22
ectrims highlights: ai, btk inhibitors & ebv
-
3:37
tumor-intrinsic resistance to immunotherapies in multiple myeloma
-
1:26
the imsavar project: making immunomodulatory therapies safer
-
2:00
dr. gershenson on evolution of targeted therapies for rare gynecologic malignancies
-
1:50
minimally invasive heart and vascular procedures
-
14:24
angiocrine bioscience
-
2:40
venetoclax and ruxolitinib treatment strategies for myeloma
-
3:52
exploring treatment strategies for claudication in vascular medicine
-
1:30
biologics and biosimilars: increasing treatment options
-
1:06
advances in cell therapies by the cell therapies core
-
4:51
angiology and vascular surgery department | dr. borja merino | imed hospitales